# Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

> **NCT01375140** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Myeloproliferative Diseases

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Lenalidomide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01375140
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-22
- **Primary completion:** 2018-09-05
- **Final completion:** 2018-09-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01375140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01375140, "Ruxolitinib and Lenalidomide for Patients With Myelofibrosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01375140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*